Welcome to our dedicated page for EUROFINS SCIENTIFIC SA news (Ticker: ERFSF), a resource for investors and traders seeking the latest updates and insights on EUROFINS SCIENTIFIC SA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EUROFINS SCIENTIFIC SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EUROFINS SCIENTIFIC SA's position in the market.
Eurofins announces the availability of new assays for rapid identification of SARS-CoV-2 variants B.1.1.7, B.1.351, and B.1.1.248, offering them free to public health institutions lacking rapid detection capabilities. Current methods take 3-5 days, risking further spread of these more infectious variants. The GSD NovaType SARS-CoV-2 Detect & ID test, utilized in Europe, provides qualitative detection with a one-hour run time. Additional kits for other variants are expected mid-February.
FAQ
What is the current stock price of EUROFINS SCIENTIFIC SA (ERFSF)?
What is the market cap of EUROFINS SCIENTIFIC SA (ERFSF)?
